MESOBLAST LIMITED Market Briefing - Mr Michael Spooner, Executive Chairman

Sydney, Mar 24, 2006 (ABN Newswire) - MESOBLAST LIMITED Market Briefing - Mr Michael Spooner, Executive Chairman; Boardroomradio is pleased to announce that MESOBLAST LIMITED (ASX: MSB) has published an audio file. The following presentation "" is now available as an instant audio download to your computer. You may also transfer this information to your listening device as an IPod podcast.

The BRR service is based on streaming audio sent in compressed form over the internet and displayed as it arrives. You do not have to wait for the whole file to be downloaded before you can hear it, instead the media is sent in a continuous stream and is played immediately as it reaches your computer. Please note that during live broadcasts there can be a delay of approximately 1-2 minutes, depending on traffic through your Internet Service Provider.

Broadcaster: MESOBLAST LIMITED (ASX: MSB)

Broadcast Title: No Title

Broadcast Type: Audio stream

View the Audio stream for MESOBLAST LIMITED (ASX: MSB) by clicking on the following links.

Display in Windows Media Player
http://www.boardroomradio.com/event/MSB/1282/8235/wmp/221.242.254.150/wsl.wmp?

or:

Display in MP3 Player or Transfer to Portable Podcast Device
http://www.boardroomradio.com/event/MSB/1282/8235/mp3/221.242.254.150/wsl.mp3?

Computers set up for access to the Internet, including at least a 28.8k modem and sufficient memory and hard disk space to run Windows Media Player or Real Player, should be able to run BRR media files.

About MESOBLAST LIMITED

Mesoblast Limited (ASX:MSB; USOTC:MBLTY) is an Australian biotechnology company committed to the development of novel treatments for orthopaedic conditions, including the rapid commercialisation of a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage. Our focus is to progress through clinical trials and international regulatory processes necessary to commercialise the technology in as short a timeframe as possible.

Mesoblast has the worldwide exclusive rights for a series of patents and technologies that have been developed over more than 10 years and which relate to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The Company has also acquired a substantial interest in Angioblast Systems Inc, an American company developing the platform MPC technology for the treatment of cardiovascular diseases, including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology. Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones.

About Boardroomradio

Sydney-based Boardroomradio (BRR) is an Investor Relations multi-media portal delivering audio webcasts to the investment community, including brokers, fund managers, analysts, and private investors.